Corporate Governance - The company maintains complete control over its assets, with no instances of asset occupation by controlling shareholders or other shareholders[8]. - The company operates independently from its controlling shareholders, with a complete organizational structure and the ability to make independent financial decisions[7]. - The supervisory board consists of 4 members, including 2 employee supervisors, ensuring compliance with legal requirements[6]. - The company has established an independent financial department and a financial management system, ensuring independent financial operations[10]. - The company has a clear and independent property relationship with its controlling shareholders, with no guarantees provided for shareholders' debts[8]. - The company has no competition with its controlling shareholders, as its business activities are entirely independent[7]. - The company has implemented a robust internal control system in accordance with relevant laws and regulations[4]. - The company has actively participated in shareholder meetings and has adhered to the required procedures for supervisory board meetings[6]. - The company has not raised any objections to matters discussed in the board meetings during the reporting period[55]. Management and Remuneration - The company reported a total shareholding of 444,031 shares for the president, Liu Kailie, at the end of the period[24]. - The company has not experienced any changes in shareholding for the board members and supervisors during the reporting period[25]. - The chairman, Lei Jufang, has been in position since October 8, 2007, and is set to serve until May 13, 2024[26]. - The company has a total of 266,418 shares held by the Vice President of Operations, Xiao Jianqin, at the end of the period[24]. - The company has a total of 177,612 shares held by Vice President Wang Zhiqiang at the end of the period[24]. - The company has a total of 192,945 shares held by Vice President Li Jun at the end of the period[24]. - The company has a total of 133,209 shares held by Chief Scientist Chen Weiwu at the end of the period[24]. - The company has maintained a stable management team with no resignations or dismissals reported during the period[25]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 13.9881 million CNY[33]. - Liu Kailie, the President and Director, received a pre-tax remuneration of 2.8195 million CNY[33]. - The company has 7 directors, including 3 independent directors, and 4 supervisors[33]. - The performance evaluation for senior management is based on company performance and individual achievements, with annual target assessment agreements signed[33]. - The independent directors' remuneration standards are determined by the shareholders' meeting, covering reasonable expenses incurred while exercising their duties[33]. - The company has established a Nomination and Remuneration Committee to review and formulate remuneration policies for directors and senior management[33]. - The company’s operational vice president, Xiao Jianqin, received a pre-tax remuneration of 1.2712 million CNY[33]. - The total number of senior management personnel is 9, with one serving concurrently as a director[33]. - The remuneration for the independent director, Guo De'an, was 46,600 CNY[33]. - The company has a performance-based remuneration system that aligns with its operational results[33]. Financial Performance - The company reported a total revenue of 1.2 billion yuan for the fiscal year 2022, representing a year-over-year increase of 15%[39]. - The net profit attributable to shareholders for the fourth quarter was RMB 112,865,167.25, reflecting a decrease from the third quarter's RMB 127,221,135.64[117]. - The company reported a total net profit attributable to shareholders of RMB 472,408,229.26 for the entire year of 2022, marking a year-on-year increase of 15%[117]. - The gross profit margin for the year was reported at 60%, indicating strong profitability in its core business operations[1]. - The net profit attributable to shareholders for 2022 was ¥472,408,229.26, a decrease of 34.01% from ¥715,876,201.47 in 2021[137]. - The net profit excluding non-recurring gains and losses was ¥440,018,192.00, up 27.57% from ¥344,932,156.80 in 2021[137]. - The basic earnings per share for 2022 was ¥0.8919, down 34.14% from ¥1.3542 in 2021[137]. - The total assets attributable to shareholders at the end of 2022 were ¥5,886,644,252.44, an increase of 5.73% from ¥5,567,753,848.57 at the end of 2021[137]. Market Expansion and Product Development - The company is actively involved in various associations and has received multiple honors for its contributions to the industry[26]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[39]. - New product launches included two innovative herbal medicine products, projected to contribute an additional 200 million yuan in revenue[39]. - The company plans to invest 100 million yuan in digital marketing initiatives to boost brand awareness[39]. - The company aims to achieve the strategic goal of being the "first in external pain relief and first in the Tibetan medicine market" through a multi-product marketing approach and modernization of Tibetan medicine[66]. - In 2023, the company initiated a new chapter in multi-product marketing, focusing on consolidating market share for core products and accelerating growth in key varieties such as Tie Bang Chui Pain Relief Ointment and Qing Peng Ointment[66]. - The company plans to expand its product cluster in seven major therapeutic areas, including respiratory, pediatrics, gynecology, digestion, cardiovascular, and neurology, with specific products targeting unmet clinical needs[69]. - The company is focusing on digital marketing transformation and expanding e-commerce platform sales to adapt to consumer trends[157]. - The company is enhancing its distribution channels, particularly focusing on B2C and O2O models to improve customer reach[1]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[1]. Research and Development - Research and development expenses increased by 30% to 150 million yuan, focusing on new drug formulations[39]. - The company is committed to enhancing its research and development capabilities, focusing on the modernization of Tibetan medicine and the development of new products based on clinical needs[70]. - The company has established a strong R&D platform for Tibetan medicine products, ensuring quality and safety throughout the product lifecycle[70]. - The company has optimized its R&D system, enhancing product development capabilities and accelerating product launches[172]. - The company completed the key research tasks of the national key R&D project on Tibetan medicine, demonstrating significant advantages of its products in treating acute ischemic stroke compared to placebo[197]. - The clinical research on Baipai Ointment for diabetic peripheral neuropathy showed significant improvement in patients' symptoms of numbness and pain[197]. - The clinical study results indicated that Baipai Ointment significantly alleviates pain and improves function in patients with lumbar disc herniation[197]. - The company published a total of 24 papers during the reporting period, including 5 SCI articles[197]. - The company completed the Phase III clinical study of Cuotang Granules, showing good efficacy and safety in treating common cold symptoms[198]. - The production line for Cuotang Granules has been licensed, ensuring smooth progress for commercialization[198]. Sustainability and Compliance - The company is committed to complying with national policies and enhancing its product's clinical evidence chain to ensure sustainable business development[63]. - The company is committed to sustainable development practices, being recognized as a national green demonstration factory[188]. - The company emphasizes sustainable resource development and quality standard improvement in its research tasks[131]. - The company has established wild nurturing and artificial planting bases for Tibetan medicinal materials[163]. - The company has established a cultivation area of 100 acres for medicinal materials as part of a national major project for the cultivation demonstration base of Tibetan medicinal materials[174].

索 引 号 bm56000001/2023-00012426 分 类 发布机构 发文日期 1698971601000 名 称 关于对中勤万信会计师事务所（特殊普通合伙）及石朝欣、孙红玉采取出具警示函措施的决 定 西 藏 证 监 局 文 号 〔2023〕33号 主 题 词 2 0 2 3 年 1 0 月 3 1 日 经查，中勤万信会计师事务所（特殊普通合伙，以下简称中勤万信）在对 奇正藏药股份有限公司（以下简称奇正藏药）2022年年度报告执行审计工作 时，未能识别出公司与其控股股东共计1.11亿元的关联交易业务，导致奇正藏 药2022年年度审计报告及关联方资金占用报告披露不准确。 上述行为违反了《中国注册会计师审计准则第1323号——关联方》（2010 年修订）第二十六条第二项的规定、《上市公司信息披露管理办法》第四十五 条第一款、第四十六条的规定，签字会计师石朝欣、孙红玉对上述违规事项负 有主要责任。根据《上市公司信息披露管理办法》第五十五条规定，我局决定 对中勤万信及签字会计师石朝欣、孙红玉采取出具警示函的监督管理措施。你 们应认真吸取教训，严格遵照相关法律法规和中国注册会计师审计准则的规 定，切实提高审计 ...

雷菊芳、刘凯列、姚晓梅、冯平: | 索 | 引 | 号 | bm56000001/2023-00012427 | 分 | 类 | | --- | --- | --- | --- | --- | --- | | | 发布机构 | | 发文日期 1698971696000 | | | | 名 | | 称 | 关于对雷菊芳、刘凯列、姚晓梅、冯平采取出具警示函措施的决定 | | | | 文 | | 号 | 〔2023〕34号 题 | 主 | 词 | 西 藏 证 监 局 关于对雷菊芳、刘凯列、姚晓梅、冯平采取出具警示函措施的决定 〔2023〕34号 经查，西藏奇正藏药股份有限公司（以下简称奇正藏药或公司）与控股股 东甘肃奇正实业集团有限公司（以下简称奇正实业）自2022年8月至2023年3月 期间，累计交易可转让大额存单金额15,100万元，其中奇正藏药及其子公司向 奇正实业出售大额存单9,300万元，公司购买奇正实业大额存单5,800万元，该 行为构成关联交易且达到董事会审议及信息披露标准，但公司并未履行审议程 序，也未在临时报告及2022年年报、2023年半年报中披露相关信息。 雷菊芳作为公司董事长、刘凯列作为公司 ...

西藏奇正藏药股份有限公司（以下简称"公司"）于 2023 年 11 月 3 日召开 第五届董事会第二十七次会议、第五届监事会第十八次会议，审议通过了《关于 补充确认 2023 年度大额存单关联交易的议案》，具体情况公告如下： 一、关联交易概述 1、关联交易基本情况 2023年度，西藏奇正藏药股份有限公司（以下简称"公司"）受让甘肃奇正 实业集团有限公司（以下简称"奇正集团"）大额存单合计7,000万元。 | 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2023-057 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 关于补充确认 2023 年度大额存单关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2、奇正集团为公司控股股东，以上交易构成关联交易。 3、公司召开第五届董事会第二十七次会议、第五届监事会第十八次会议， 对上述关联交易进行了补充确认，关联董事、关联监事回避表决。公司独立董事 对该事项进行了事前认可，并发表了同意的独立意见。本次关联交易 ...

| 证券代码：002287 | 证券简称：奇正藏药 公告编号：2023-058 | | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | 西藏奇正藏药股份有限公司 关于公司及子公司签订 《募集资金三方监管协议之补充协议》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 西藏奇正藏药股份有限公司（以下简称"公司"、"奇正藏药"）第五届董 事会第二十七次会议审议通过了《关于公司及子公司签订<募集资金三方监管协 议之补充协议>的议案》，为规范公司募集资金管理和使用，保护投资者的权益， 根据《深圳证券交易所上市公司规范运作指引》、《上市公司监管指引第 2 号— 上市公司募集资金管理和使用的监管要求》等相关法律法规以及公司募集资金管 理制度的相关规定，公司与兴业银行股份有限公司兰州分行（以下简称"兴业银 行"）、保荐机构申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承 销保荐"）拟签订《募集资金三方监管协议之补充协议》（以下简称"《三方协 议补充协议（兴业 41441）》"）；公司及子公司甘肃佛阁藏药有限公司（以下 简称"甘肃佛 ...

| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2023-055 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 第五届监事会第十八次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 1、西藏奇正藏药股份有限公司（以下简称"公司"）第五届监事会第十八次 会议于 2023 年 11 月 3 日以通讯形式召开； 2、会议通知于 2023 年 10 月 27 日以电子邮件、电话、信息等方式发出； 3、出席本次会议的监事应为 4 人，实到 4 人； 4、会议由公司监事会主席贾钰女士召集并主持； 5、本次会议的出席人数、召集召开程序、议事内容符合《公司法》和《公 司章程》的相关规定。 二、监事会会议审议情况 1、审议通过了《关于补充确认 2022 年度大额存单关联交易的议案》； 经审议，监事会认为，为满足公司资金使用需求，公司及子公司与关联方转 让或受让大额存单，符合公司经营发展需要，该等关联交易定价合理、公允，不 存在损害公司和股东特别是中 ...

西藏奇正藏药股份有限公司 审计报告 勤信审字【2023】第 1073 号 目 录 | 内 容 | 页 次 | | --- | --- | | 一、审计报告 | 1-4 | | 二、已审财务报表 | | | 1.合并资产负债表 | 5-6 | | 2.母公司资产负债表 | 7-8 | | 3.合并利润表 | 9 | | 4.母公司利润表 | 10 | | 5.合并现金流量表 | 11 | | 6.母公司现金流量表 | 12 | | 7.合并股东权益变动表 | 13-14 | | 8.母公司股东权益变动表 | 15-16 | | 三、财务报表附注 | 17-113 | 中勤万信会计师事务所 地址：北京西直门外大街 112 号阳光大厦 10 层 电话：（86-10）68360123 传真：（86-10）68360123-3000 邮编：100044 审 计 报 告 勤信审字【2023】第 1073 号 西藏奇正藏药股份有限公司全体股东： 一、审计意见 我们审计了西藏奇正藏药股份有限公司（以下简称"奇正藏药"）财务报表， 包括 2022 年 12 月 31 的合并及母公司资产负债表，2022 年度的合并及母公司利 润 ...